Treatment patterns and duration in post-menopausal women with HR+/HER2− metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004–2010)

References

• National Cancer Institute. SEER Cancer Statistics Factsheets: All Cancer Sites. 2014. Available at: http://seer.cancer.gov/statfacts/html/all.html [Last accessed 6 June 2014]
   Google Scholar
• Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010;28:3271-7
   PubMed Web of Science ®Google Scholar
• Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007;8:235-44
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16
   PubMed Web of Science ®Google Scholar
• Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529-37
   PubMed Web of Science ®Google Scholar
• Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83
   PubMed Web of Science ®Google Scholar
• Clemons M, Danson S, Hamilton T, Goss P. Locoregionally recurrent breast cancer: incidence, risk factors and survival. Canc Treat Rev 2001;27:67-82
   PubMed Web of Science ®Google Scholar
• Clark GM, Sledge GW Jr, Osborne CK, McGuire WL. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. 2013. Available at: http://infoonco.es/wp-content/uploads/2011/10/breast_cancer_2.2013.pdf [Last accessed 6 June 2014]
   Google Scholar
• Swallow E, Zhang J, Thomason D, et al. Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002–2012. Curr Med Res Opin 2014;30:1537-45
   Google Scholar
• Roche H, Vahdat LT. Treatment of metastatic breast cancer: second line and beyond. Ann Oncol 2011;22:1000-10
   PubMed Web of Science ®Google Scholar
• Herynk MH, Fuqua SA. Estrogen receptor mutations in human disease. Endocr Rev 2004;25:869-98
   PubMed Web of Science ®Google Scholar
• Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. Pathways to tamoxifen resistance. Canc Lett 2007;256:1-24
   PubMed Web of Science ®Google Scholar
• Creighton CJ, Casa A, Lazard Z, et al. Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol 2008;26:4078-85
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer. Breast 2003;12:362-7
   PubMed Web of Science ®Google Scholar
• Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233-47
   PubMed Web of Science ®Google Scholar
• Encarnacion CA, Ciocca DR, McGuire WL, et al. Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Canc Res Treat 1993;26:237-46
   PubMed Web of Science ®Google Scholar
• Kuukasjarvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996;14:2584-9
   PubMed Web of Science ®Google Scholar
• Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520-9
   PubMed Web of Science ®Google Scholar
• Johnston SR, Schiavon G. Treatment algorithms for hormone receptor-positive advanced breast cancer: going forward in endocrine therapy-overcoming resistance and introducing new agents. Am Soc Clin Oncol Educ Book 2013:e28-36
   Google Scholar
• Yardley DA, Kaufman PA, Brufsky A, et al. Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Canc Res Treat 2014;145:725-34
   PubMed Web of Science ®Google Scholar
• Carlson RW, O'Neill A, Vidaurre T, et al. A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer. Breast Canc Res Treat 2012;133:1049-56
   PubMed Web of Science ®Google Scholar
• Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883-90
   PubMed Web of Science ®Google Scholar
• Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594-600
   PubMed Web of Science ®Google Scholar
• Mouridsen H, Gershanovich M, Sun Y, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758-67
   PubMed Web of Science ®Google Scholar
• Pronzato P, Rondini M. First line chemotherapy of metastatic breast cancer. Ann Oncol 2006;17(Suppl 5):v165-8
   PubMed Web of Science ®Google Scholar
• Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664-70
   PubMed Web of Science ®Google Scholar
• Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:1142-52
   PubMed Web of Science ®Google Scholar
• Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453-61
   PubMed Web of Science ®Google Scholar
• Gong DD, Man CF, Xu J, Fan Y. Fulvestrant 250 mg versus anastrozole 1 mg in the treatment of advanced breast cancer: a meta-analysis of randomized controlled trials. Asian Pac J Canc Prev 2014;15:2095-100
   PubMed Web of Science ®Google Scholar
• Robertson JF, Llombart-Cussac A, Rolski J, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530-5
   PubMed Web of Science ®Google Scholar